These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8116135)

  • 1. Primary therapy of metastatic prostate carcinoma with depot gonadotropin-releasing hormone analogue goserelin versus estramustine phosphate. The Prostate Cancer Study Group.
    Kühn MW; Weissbach L; Hinke A
    Urology; 1994 Feb; 43(2 Suppl):61-7. PubMed ID: 8116135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estramustine phosphate for preventing flare-up in luteinizing hormone-releasing hormone analogue depot therapy.
    Shimizu TS; Shibata Y; Jinbo H; Satoh J; Yamanaka H
    Eur Urol; 1995; 27(3):192-5. PubMed ID: 7541359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    Lundgren R; Nordle O; Josefsson K
    J Urol; 1995 May; 153(5):1580-6. PubMed ID: 7714978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final report on low-dose estramustine phosphate (EMP) monotherapy and very low-dose EMP therapy combined with LH-RH agonist for previously untreated advanced prostate cancer.
    Kitamura T; Suzuki M; Nishimatsu H; Kurosaki T; Enomoto Y; Fukuhara H; Kume H; Takeuchi T; Miao L; Jiangang H; Xiaoqiang L
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S34-40. PubMed ID: 20094950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
    Dimopoulos MA; Kiamouris C; Gika D; Deliveliotis C; Giannopoulos A; Zervas A; Alamanis C; Constantinidis C; Koutsilieris M
    Urology; 2004 Jan; 63(1):120-5. PubMed ID: 14751362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ; Morales A
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).
    Newling DW; Fossa SD; Tunn UW; Kurth KH; de Pauw M; Sylvester R
    J Urol; 1993 Dec; 150(6):1840-4. PubMed ID: 8230517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments.
    Elomaa I; Kellokumpu-Lehtinen P; Rannikko S; Alfthan O
    Eur Urol; 1991; 19(1):12-5. PubMed ID: 1706666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of estramustine phosphate for hormone refractory prostate cancer patients following androgen deprivation therapy.
    Hirano D; Minei S; Kishimoto Y; Yamaguchi K; Hachiya T; Yoshida T; Yoshikawa T; Endoh M; Yamanaka Y; Yamamoto T; Satoh Y; Ishida H; Okada K; Takimoto Y
    Urol Int; 2005; 75(1):43-9. PubMed ID: 16037707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical evaluation of flutamide and estramustine as initial treatment of metastatic carcinoma of prostate.
    Johansson JE; Andersson SO; Beckman KW; Lingårdh G; Zador G
    Urology; 1987 Jan; 29(1):55-9. PubMed ID: 3798631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.
    Brogden RN; Faulds D
    Drugs Aging; 1995 Apr; 6(4):324-43. PubMed ID: 7613021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of stage D hormone-resistant carcinoma of the prostate with estramustine phosphate.
    Benson RC; Wear JB; Gill GM
    J Urol; 1979 Apr; 121(4):452-4. PubMed ID: 439216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
    J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate.
    Roessler W; Hinke A; Wieland WF
    Urology; 1994 Feb; 43(2 Suppl):57-60. PubMed ID: 8116134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area.
    Soloway MS; Beckley S; Brady MF; Chu TM; deKernion JB; Dhabuwala C; Gaeta JF; Gibbons RP; Loening SA; McKiel CF; McLeod DG; Pontes JE; Prout GR; Scardino PT; Schlegel JU; Schmidt JD; Scott WW; Slack NH; Murphy GP
    J Urol; 1983 Jan; 129(1):56-61. PubMed ID: 6338251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.
    Iversen P; Rasmussen F; Asmussen C; Christensen IJ; Eickhoff J; Klarskov P; Larsen E; Mogensen P; Mommsen S; Rosenkilde P
    J Urol; 1997 Mar; 157(3):929-34. PubMed ID: 9072602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center.
    Denis LJ; Carnelro de Moura JL; Bono A; Sylvester R; Whelan P; Newling D; Depauw M
    Urology; 1993 Aug; 42(2):119-29; discussion 129-30. PubMed ID: 8367920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation with long-term follow-up of flutamide and estramustine as initial treatment of metastatic carcinoma of the prostate.
    Johansson JE; Andersson SO; Beckman KW; Zador G
    Am J Clin Oncol; 1988; 11 Suppl 2():S183-6. PubMed ID: 3242386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.